Horizon Therapeutics plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 06, 2019 08:00 am

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2019 of inducement restricted stock units for an aggregate of 53,008 ordinary shares to 31 new employees.

The restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.

The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

About Horizon Therapeutics plc

Horizon Therapeutics plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs.

Tina Ventura
Senior Vice President, Investor Relations
[email protected]

Ruth Venning
Executive Director, Investor Relations
[email protected]

U.S. Media Contact:
Geoffrey Curtis
Executive Vice President, Corporate Affairs & Chief Communications Officer
[email protected]

Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]